Small Cell Lung Cancer

The findings are based off an analysis of 98,159 individuals.

Veterans residing in rural areas were less likely to complete annual repeat lung cancer screenings compared with those living in a nonrural location, with reduced uptake of initial lung cancer screening also found among eligible veterans in rural vs nonrural locations.

A subsequent analysis suggested, however, that segmentectomy was preferable to lobectomy in many cases.

A new meta-analysis found that more severe emphysema is associated with an increased risk of lung cancer.

A new review article summarizes current approaches to precision medicine in lung cancer.

Among a group of patients with lung cancer who were not suitable for anticancer treatment, the researchers found that 40% underwent additional investigations after their initial CT scan before eventually receiving best supportive care.

Researchers in Pennsylvania conducted a randomized controlled trial to understand the effect of patient outreach on lung cancer screening rates.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the potential of certain drug classes for lung cancer.

A decade’s worth of data included more than 5 million social determinants of health (SDOH) attributes across nearly 2 million clinical notes from the patient visits extrapolated from a natural language processing system.

Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.

Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology.

Findings suggest measuring excess weight in patients may help predict the development of radiation pneumonitis.

Although the widespread use of low dose computed tomography screening for lung cancer has led to improved mortality in recent years, disparities in uptake persist throughout the United States.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the need for increased lung cancer screening among patients who have no tobacco use history.

Melissa Johnson, MD, program director of lung cancer research at Sarah Cannon Research Institute, outlines the importance of diverse patient populations in cancer trials.

Researchers reviewed clinical trial data of 19 FDA-approved treatments for non-small cell lung cancer.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, explains factors inhibiting uptake of next-generation sequencing testing among patients with lung cancer.

Researchers assessed the incidence of this potentially deadly complication among patients who recently underwent surgery for their non-small cell lung cancer (NSCLC).

Authors outlined advancements in chimeric antigen receptor-modified T (CAR-T) cell therapy for lung cancer, and accompanying challenges.

Findings of a meta-analysis suggest adding antiangiogenics to second-line treatment in non–small cell lung cancer (NSCLC) may improve survival outcomes, especially in younger patients.

Researchers used data to develop a nomogram that identified factors associated with worse prognoses in patients with non–small cell lung cancer (NSCLC) and liver metastases.

Writing in Journal of Internal Medicine, researchers examine potential barriers inhibiting uptake of low-dose CT lung cancer screening in Europe.

A recent study demonstrates certain driver mutations in patients with non–small cell lung cancer (NSCLC) may shorten disease-free survival after combination neoadjuvant immunotherapy and chemotherapy.

Integrating plasma next-generation sequencing (NGS) alongside tissue testing when determining lung cancer diagnosis may improve outcomes for patients.

Researchers analyzed declines in clinical trial enrollment and asked sites what mitigation strategies they employed to meet the reduction.

Researchers compared drug costs among hospitals, specialty pharmacies, and physician offices.

Patients who utilized a patient-reported outcome (PRO) symptom measurement tool reported superior postdischarge outcomes after lung cancer surgery compared with those who received usual care.

Patients with non–small cell lung cancer (NSCLC) reported superior mental health well-being during the COVID-19 pandemic compared with a control population that did not have cancer.

The national coverage determination will help detect early non-small cell lung cancer, CMS said.

Using data from a meta-analysis, researchers determined tumor-stroma ratio could serve as a survival predictor in non–small cell lung cancer (NSCLC).